Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) is currently developing a genetic approach to regulating NR2F6 levels in human T cells. The Company has recently received unexpected and potentially extremely useful data from one of its contract research organizations (CRO) retained to perform experimental studies on the Company’s DuraCAR CAR T-cell therapeutic. These studies demonstrated that T cells which express the chimeric antigen receptor (CAR) construct expressing siRNA for NR2F6 can be successfully created.
“A second unrelated CRO is currently performing qRT-PCR tests to determine if NR2F6 mRNA is elevated or inhibited by our CAR in T-Cells,” says Dr. Harry Lander, Chief Scientific Consultant to the Company.” If NR2F6 mRNA is suppressed (stimulating certain immune functions) then this product shows potential for treatment of cancer and if NR2F6 mRNA is elevated (suppressing certain immune functions) then the product shows potential for treatment of autoimmune disorders.”
Once the Company receives the data, it will analyze the results and report the findings in a press release in order to keep the company’s shareholders informed of its progress.
“We know our shareholders are anxious to hear about our results surrounding modifying NR2F6 levels in CAR T-cells and we will get this data out as soon as we can,” says Dr. David Koos, Chairman and CEO of the company.
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (OTC-PINK: RGBP) and (OTC-PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Related News
Another Two-Plasmid AAV Gene Therapy Enters Clinical Trial: Gene Vector Biotechnology’s JWK001 Pioneers in Treating nAMD
On November 30, 2023, Gene Vector Biotechnology Co., Ltd. in Chengdu, China, received approval from the National Medical Products Administration's Center for Drug Evaluation (CDE) for the clinical trial of JWK001, a Class I gene therapy drug for treating neovascular...
Accelerating Gene Therapy Production: Combining next-generation AAV vectors and artificial intelligence (AI)
Recently, the France-based WIDGeT consortium emerged from a collaboration between Sanofi, WhiteLab Genomics, the TaRGeT Laboratory at Nantes University, and Institut Imagine. Scientists and companies in this consortium hope to speed up the development of gene...
REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal dose determination and initiation of pivotal program in 2024...
FDA is investigating whether CAR-T, a cancer therapy pioneered at Penn, can cause lymphoma
Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug...
Plasmids GMP Services
AAV GMP Services
